COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D03EHN
|
|||
Drug Name |
Avdoralimab
|
|||
Synonyms |
IPH5401
|
|||
Drug Type |
Monoclonal antibody
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Phase 2 | [1] | |
Therapeutic Class |
Antiviral Agents
|
Target | Top | |||
---|---|---|---|---|
Target(s) | HUMAN C5a receptor (C5aR) | Target Info | Inhibitor | [2], [3] |
Blockade of the C5a and C5aR interaction by an anti-C5aR antibody avdoralimab can significantly reduce alveolar macrophage infiltration and IFN- receptor expression in lung tissue, resulting in alleviation of tissue damage induced by the excessive immune response in patients with COVID-19. |
References | Top | |||
---|---|---|---|---|
1 | ClinicalTrials.gov (NCT04371367) Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE ). U.S. National Institutes of Health. | |||
2 | Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect. 2018 Apr 24;7(1):77. | |||
3 | Complement as a target in COVID-19 Nat Rev Immunol. 2020 Apr 23. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.